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The purpose of this study was to determine the activity of the autonomic nervous system (ANS), using spectral 
analysis of the heart rate variability (HRV) in the model of partial bladder outlet obstruction (PBOO) in rats treated 
with selected non-steroidal anti-inflammatory drugs (NSAID): piroxicam (PRX) or meloxicam (MLX), and 
following administration of PGF2α prostaglandin analogue (Enzaprost F5). Neither the use of PGF2α analogue nor 
of MLX, caused significant changes in the HRV spectrum (except for HRV spectrum total power reduction with 
MLX). The use of PRX caused reduction of the total power and powers of all components of the HRV spectrum 
(except for VLF). Moreover, increased nLF and reduced nHF were observed. The obtained results suggest that the 
total prostaglandin synthesis block with a non-selective cyclooxygenase inhibitor (PRX) results in reduced ANS 
total activity, with decreased parasympathetic activity and a relative sympathetic predominance. The preferential 
cyclooxygenase-2 block (MLX) caused reduction of the total ANS activity as well, however with no clear 
disproportion of any part of the ANS. Therefore, prostaglandin synthesis inhibition and associated decrease of 
parasympathetic activity may constitute an additional and favourable feature of NSAID pharmacodynamics in the 
treatment of BPH.
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Bladder overactivity as a secondary condition (secondary overactive bladder; OAB) develops 
in course of organic illnesses. One of them is benign prostatic hyperplasia (BPH). In course 
of that disease, bladder overactivity is a result of compression of hypertrophic prostatic tissue 
on proximal section of the urethra, resulting in compromised urine outflow and progressive 
pressure increase in lower urinary tract. 
Pathophysiological description of BPH postulates the role of higher dihydrotestosterone 
and fibroblastic/vascular growth factors content in prostatic tissues as well as local prostatic 
hypoxia and inflammation that result in remodelling of prostatic tissues (8, 34). There are 
also reports regarding a close association between BPH development and co-existence of 
metabolic syndrome in the same patient. That would suggest the role of hyperinsulinaemia 
and insulin resistance combined with higher sympathetic activity and explained exacerbation 
of BPH in patients with coexistent diabetes (6). 
The current, classic pharmacotherapy of BPH involves the use of α-1 adrenolytics (α-1 
adrenergic receptor antagonists) and 5-α reductase inhibitors as monotherapy or combined 
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therapy (23, 28). There are also reports indicating a favourable effect of cholinolytic drugs 
and phosphodiesterase inhibitors – those two classes of compounds are being tested in several 
clinical trials assessing their efficacy and safety in BPH pharmacotherapy (28). 
In face of a relatively few pharmacological options of BPH therapy, studies focused on 
development of new, potentially effective compounds are being performed. Potential new 
drugs are: β3 adrenergic drugs (β3 adrenergic receptor agonists), P2X purinergic receptor, 
endoteline receptors (ETA / ETB) or angiotensin receptors (AT1 / AT2) antagonists, vitamin 
D3 analogues and Rho kinase inhibitors (2, 41).
Among the currently studied drugs for BPH treatment there are also non-steroidal anti-
inflammatory drugs (NSAID), both non-selective and selective cyclooxygenase (COX) 
inhibitors. Araki et al. (3) demonstrated that administration of loxoprofen, as an addition to 
the standard α-1 adrenolytic BPH therapy, reduced nocturnal miction episodes. Falahatkar et 
al. (14) demonstrated that the addition of 100 mg celecoxib to the standard therapy with α-1 
adrenolytics and 5-α reductase inhibitors in patients with multiple nocturia episodes caused 
reduction of frequency of those episodes by half. Effectiveness and efficacy of NSAID 
supplementation of BPH pharmacotherapy were also demonstrated by St. Sauver et al. (38) 
who demonstrated that everyday use of NSAID (aspirin in 80% of subjects; ibuprofen, 
diclofenac or naproxen in remaining 20%) was negatively correlated with BPH symptoms 
exacerbation. Moreover, Kahokehr et al. (19) performed a systematic review of clinical trials 
focusing on the evaluation of clinical usefulness of NSAID in BPH. They confirmed existence 
of numerous and positive study reports, but at the same time they stated that aspects associated 
with safety of long-term use of those drugs in the condition remained unknown (19).
Considering the incomplete description of NSAID pharmacodynamics in BPH it seems 
important to determine if those drugs exert their potentially beneficial effect on BPH-
associated bladder overactivity symptoms also by modulation of activity of the autonomic 
nervous system (ANS).
As BPH may be relatively easily modelled in study animals by surgical formation of a 
partial bladder outlet obstruction (PBOO), experimental simulation studies are possible (32). 
Also, the functional status of the ANS may be indirectly evaluated based on the assessment 
of the heart rate variability (HRV), based on recording of a mean time between subsequent 
N-N (normal–normal) intervals in ECG in the aspect of spectral (frequency) analysis (26). 
Therefore, our purpose was to evaluate the functional status of ANS using the HRV 
methodology in course of PBOO in rats treated with non-selective (COX-1 and -2 blocking) 
or with preferential (COX-2 blocking) cyclooxygenase inhibitor, as well as with PGF2α 
prostaglandin analogue.
Materials and Methods
Ethical aspects of the experiment
The medical experiment constituting the basis for this report was approved by the 1st Local 
Bioethics Committee for Animal Experiments in Krakow (no. 124/2013).
General plan of the experiment
The study was carried out in four groups (10 participants each) of 8-week-old Wistar rats. 
Group 1 was the control group, and pharmacological agents were administered to animals in 
groups 2–4. On the first day of the experiment all animals had the procedure of partial bladder 
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outlet obstruction. The PBOO model was evoked according to a surgical technique described 
in detail in one of our previous work (12).
On day 3 after surgery, study agents were introduced (intraperitoneally; i.p.) to groups 
2–4 and placebo was introduced in group 1. The administration was continued every other 
day. On day 14 after the PBOO surgery all animals had ECG recordings with subsequent 
analysis of heart rate variability. Moreover, after ECG registration, urodynamic studies were 
performed to assess bladder contractility due to infravesical partial obstruction in both control 
and treated rats. Standard urodynamic parameters were estimated. The detailed methodology 
of urodynamic recordings applied by us is given in our other paper (13). Then, following 
administration of a lethal dose of pentobarbital, cystectomy was performed in order to 
measure the bladder wet weight (BWW) and for subsequent histopathological evaluation. 
Initial (at the day of PBOO surgery) and final (on the day of ECG record) animal body weight 
was determined in all groups. Water and standard laboratory feed (Labofeed, Kcynia, Poland) 
consumption were not monitored throughout the experiment and animals had unlimited 
access to both water and feed.
Studied pharmacological agents
In all study groups, the pharmacological agents (groups 2–4) or normal saline (group 1) were 
administered intraperitoneally on the day 3, 5, 7, 9, 11 and 13 after the PBOO surgery. Group 
2 received the PGF2α prostaglandin analogue solution (commercially available product 
Enzaprost F5, ampoules 5 mg/ml, Chinoin Pharmaceutical and Chemical Works Co. Ltd., 
Budapest, Hungary); groups 3 and 4 received cyclooxygenase inhibitors: meloxicam (MLX) 
or piroxicam (PRX), respectively. In those cases also commercially available products were 
used (meloxicam – Movalis, ampoules 15 mg/1.5 ml, Boehringer Ingelheim International 
GmbH, Ingelheim am Rhein, Germany; piroxicam – Feldene, ampoules 20 mg/ml, Pfizer 
Europe, Kent, UK). Rats in the group 1 – control – received injections of normal saline at the 
mean volume corresponding to the applied doses of Enzaprost/Feldene/Movalis. In the group 
2 we used the PGF2α prostaglandin analogue solution at the dose of 200 µg/rat, corresponding 
to approx. 0.8–0.9 mg/kg b.w. Rats constituting group 3 were treated with MLX at the dose 
of 5mg/kg b.w., while animals from group 4 received PRX at the dose of 10mg/kg b.w.
Both in groups 1 and 2 one individual died during the early post-surgical period. 
Therefore, 9 animals were finally studied in both those groups. A higher mortality rate was 
observed in animals receiving MLX or PRX – 2 and 3 animals, respectively, had died before 
the final dosage of the study agent was administered. 
HRV records
On day 15 of the experiment all animals were subjected to a short-term (20 minutes) ECG 
recording under general urethane anaesthesia (1200 mg/kg b.w., Sigma-Aldrich, Poznan, 
Poland) in accordance with the details described by us elsewhere (12). The choice of that 
anaesthetic agent was based on premises that compared to other pharmacological agents for 
general anaesthesia, that one had the less pronounced depressive effect on the ANS (24, 25). 
Directly before the ECG recording study animals received an additional intraperitoneal dose 
of the study agent (groups 2–4) or of normal saline (control). 
After the registration the obtained ECG signal was evaluated visually in order to remove 
any ectopic beats, and the record was subjected to the spectral (frequency) HRV analysis 
using the Polygram set and software (ADInstruments Pty Ltd. Bella Vista, Australia; Chart 
v5.4.2 for Mac OS X Version 10.1.2).
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The spectral analysis involved evaluation of powers of components of the, so-called, 
HRV spectrum, that is distribution of changes of ECG normal-normal (N-N) beats intervals 
in relation to the cyclic, ANS-modulated stimulatory activity of the sinus node associated 
with three basic rhythms: very low (VLF), low (LF) and high (HF) frequency (26, 39). For 
the sake of this analysis we have adopted the following ranges for individual components of 
the HRV spectrum: 0.18 < VLF < 0.28 < LF < 0.78 < HF < 3. Those frequency ranges are 
similar to those adopted by Aubert et al. (0.19 < LF < 0.74 < HF < 2.5) (5) and Goncalves et 
al. (0.10 < LF < 1.0 < HF < 3.0) (15). The evaluation was completed in two ways – studying 
powers of individual, basic HRV components (VLF, LF, HF), and the total power (TP) of the 
spectrum expressed in power units [ms2], as well as analysing percent changes of individual 
components (VLF [%], LF [%], HF [%]) in relation to the total power of the spectrum, LF/
HF ratio and values of normalized nLF and nHF parameters expressed in [n.u.].
Collection of bladders and their weight and histopathological assessment: 
Following the ECG and urodynamic recordings animals in all groups were sacrificed by 
intraperitoneal administration of a lethal anaesthetic dose of pentobarbital (Morbital, 100 mg/
kg b.w., Biowet Sp. z o.o., Poland) in order to collect urinary bladders for weighing and 
histopathological evaluation (using the hematoxylin-eosin staining). Bladders with the 
proximal, ligated section of the urethra were collected during a repeated laparotomy. Excised 
bladders were delicately dried on gauze compresses and opened carefully in order to empty 
them from retained urine, weighed on analytic scales and placed in 4% formalin solution. The 
measurement of bladder wet weight (BWW) is considered a general, non-specific marker of 
its pathological histological reconstruction (35, 42), occurring in PBOO as a result of pressure 
overload.
Statistical analysis
The statistical analysis was completed with the statistical suite R.3.0.2. (R Foundation for 
Statistical Computing, Vienna, Austria).
First, variance analysis (ANOVA) was used for verification of statistically significant 
differences between four study groups. Then, in case a statistical significance was 
demonstrated for a particular analysed parameter (p < 0.05 in ANOVA), differences between 
groups 1–2 (PBOO control vs. PBOO+PGF2α), 1–3 (PBOO control vs. PBOO+MLX) and 
1–4 (PBOO control vs. PBOO + PRX) were analysed using the t-Student test. Both tests were 
made on logarithms of obtained HRV results. That procedure was applied to ensure higher 
concordance of those parameters with the normal distribution.
Results
The characteristics of study animals body weight and bladder wet weight
In the end of the experiment, reduced body weight was observed in all groups compared to 
baseline. The change was significant in group 4 (rats receiving PRX). A relatively worse 
condition of animals in that group could be associated with potential adverse effects of PRX 
on gastrointestinal (GI) tract mucosa.
The bladder wet weight was the highest in control rats and similar in group 3. Animals 
treated with PGF2α analogue and PRX were characterized by lower BWW values and the 
differences compared to the control were significant. However, the value of the bladder wet 
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weight ratio (BWW in relation to the final body weight) was tended to be lower in all treated 
groups with no statistical difference compared to the control. The characteristics of study 
animals and BWW results are presented in Table I.
Table I. Characteristics of studied groups
PBOO 
Control
Group 1
PBOO + 
PGF2α
Group 2
PBOO +  
MLX
Group 3
PBOO +  
PRX
Group 4
Statistic
Group 
1-2
Group 
1-3
Group 
1-4
Starting body 
weight [g]
230.7 ± 9.9 216.1 ± 8.1 230.6 ± 15.02 237.2 ± 14.6 0.01 NS NS
Final body weight 
[g]
213.3 ± 16.6 203.8 ± 14.9 219.8 ± 8.9 178.2 ± 10.7 NS NS 0.001
Bladder wet weight 
(BWW) [mg]
438.6 ± 
291.0
310.2 ± 
148.7
388.0 ± 195.1 288.1 ±  
234.6
0.05 NS 0.05
BWW [g]/Final 
body weight [g] 
ratio
0.0021 ± 
0.0020 
0.0015 ± 
0.0008 
0.0018 ± 
0.0010 
0.0016 ± 
0.0012
NS NS NS
Urodynamic recordings
Comparing to findings revealed in normal rats in our another study (13), the PBOO rats 
(group 1) were characterised by an increase of peak number (both total amount and peaks per 
minute) along with intercontraction interval [s], threshold pressure [cmH2O] and micturition 
voiding pressure [cmH2O] decrease. These results confirmed bladder overactivity due to 
proximal urethral obstruction in PBOO control rats (group 1). The Enzaprost/Feldene/
Movalis treated animals (groups 2–4) demonstrated similar urodynamic features, with no 
signs of statistically significant improvement of bladder functioning, although in animals 
receiving PRX a trend of bladder overactivity reduction was observed. The urodynamic 
recording examples are given in Figs 1 and 2.
Fig. 1. The example of urodynamic 
recording obtained in normal rats in 
our another study (13)
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 Fig. 2. The example of urodynamic 
recording obtained in partial  
bladder outlet obstruction (PBOO) 
control animals, confirming bladder 
overactivity
Histopathological assessment of the collected bladders
The histopathological evaluation of bladders collected from control animals (the PBOO 
group without any treatment) revealed signs of hyperaemia of the bladder wall and dilation 
of its lumen with signs of hyperaemia and oedema of the mucosal lamina propria. Moreover, 
some minor inflammatory infiltrations were revealed, made of small lymphocytes and single 
granulocytes, and a minimal hypertrophy of the bladder wall muscular coat.
In group 2 (PBOO + PGF2α) hyperaemia and dilation of the lumen were demonstrated, 
with signs of papillosis urothelialis fere completa; moreover, signs of a minor inflammation 
composed of small lymphocytes were revealed.
Bladders from PBOO animals treated with MLX (group 3) also demonstrated dilation of 
their lumen with signs of hyperaemia and marked intensification of oedema of the mucosa 
and of the whole bladder wall, with small extravasations and minor perivascular inflammatory 
infiltrations composed of small lymphocytes.
The histopathological presentation of rat bladders in group 4 (PBOO + PRX) corres-
ponded to cystitis chronica partim ulcerosa et oedema et hyperaemia passiva parietis et 
pericystitis chronica.
Based on the obtained results of histopathological analysis it may be stated that rats with 
PBOO are characterised by histological reconstruction of the bladder. Those results confirm 
effectiveness of the applied surgical method and maintenance of the PBOO model throughout 
the whole experiment.
HRV spectral (frequency) analysis 
Assessing powers of individual basic components of the HRV spectrum and its total power in 
group 2 (animals treated with PGF2α analogue), no statistically significant differences 
compared to the control were demonstrated, except for the LF/HF ratio that reached lower 
values in group 2. Animals in group 3 (MLX-treated) were characterised by statistically 
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significant lower values of total power of the spectrum and its VLF component compared to 
the control, with absence of significant differences in relation to other components (LF, HF). 
In group 4 (animals treated with PRX) we have demonstrated some statistically significant 
differences for all analysed parameters except for VLF, compared to the control. Animals in 
that group had the lowest value of LF and HF components (compared to the control and other 
groups) and the highest LF/HF ratio. Detailed numerical values are presented in Table II.
However, analysing percent distribution of individual spectral components in individual 
groups we have found no significant differences for the group 3 – animals treated with MLX 
– compared to the distribution of the control group (76.6 vs. 83.0 for %VLF, 10.2 vs. 5.8 for 
%LF and 13.2 vs. 11.2 for %HF, respectively), and for the group 2 – animals receiving 
PGF2α prostaglandin analogue (78.4 vs. 83.0 for %VLF, 8.9 vs. 5.8 for %LF and 12.7 vs. 
11.2 for %HF, respectively). On the other hand, HRV spectra for rats treated with PRX (group 
4) were significantly different compared to the control, in terms of the percent share of VLF 
(significant increase: 94.1 vs. 83.0; p = 0.05) and HF (significant decrease: 2.1 vs. 11.2; p = 
0.04) components, with no difference in terms of the percent share of the LF component (3.7 
vs. 5.8). The results (expressed in log% values) discussed above are presented in Figs 3–5.
Fig. 3. The percentage participation of the very 
low frequency (VLF) component in the heart rate 
variability (HRV) spectrum
For all 3–7 figures: A box height stands  
for the mean value of a logarithm of a parameter 
in the particular group, and whiskers present the 
95% confidence interval for the logarithm.  
Both scales: raw and logarithm, were marked to 
facilitate the interpretation. 
A result of the statistical analysis was marked in 
relation to the control group (p value or labelled 
as NS – non significant). MLX – meloxicam, 
PRX – piroxicam
Fig. 4. The percentage participation of the low 
frequency (LF) component  
in the heart rate variability (HRV) spectrum
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Fig. 5. The percentage participation  
of the high frequency (HF) component in the heart 
rate variability (HRV) spectrum
Assessing values of normalized HRV parameters we have demonstrated existence of 
statistically significant (p = 0.03) differences for the group of rats treated with PRX (group 
4): increase (nLF – 64.8) and decrease (nHF – 35.2), compared to the results obtained in the 
control group (49.1 and 50.9, respectively). In case of animals in other groups we have failed 
to demonstrate any significant differences either of nLF or of nHF compared to the control 
(group 2: nLF – 40.5, nHF – 59.6; group 3: nLF – 54.9, nHF – 45.1). The issues discussed 
above are illustrated (as log values) in Figures 6 and 7.
Fig. 6. Normalized LF (nLF) component in 
studied groups
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Fig. 7. Normalized HF (nHF) component  
in studied groups
Table II. Results of the spectral-domain HRV analysis 
PBOO Control
Group 1
PBOO+PGF2α
Group 2
PBOO+MLX
Group 3
PBOO+PRX
Group 4
Statistic
Group 
1–2
Group 
1–3
Group 
1–4
TP
[ms2]
43.34 ± 35.64 31.46 ± 10.91 17.20 ± 11.30 18.23 ± 17.84 NS 0.04 0.05
VLF
[ms2]
33.38 ± 27.94 24.22 ± 7.05 14.41 ± 12.66 17.42 ± 17.47 NS 0.05 NS
LF
[ms2]
2.99 ± 3.39 2.99 ± 2.11 1.28 ± 0.92 0.51 ± 0.42 NS NS 0.03
HF
[ms2]
6.97 ± 12.33 4.22 ± 3.25 1.52 ± 1.69 0.30 ± 0.26 NS NS 0.05
LF/HF 1.25 ± 0.75 0.76 ± 0.41 1.36 ± 0.61 1.85 ± 0.17 0.05 NS 0.02
Discussion
Considering the clinical interpretation of HRV component changes, results obtained in this 
experiment indicate existence of some significant changes in ANS function in PRX-treated 
animals with PBOO. According to the guidelines regarding HRV spectral analysis, the total 
power (TP) of the spectrum reflects the global ANS tension, the power of the HF component 
as well as the value of the normalized nHF parameter are positively correlated with 
parasympathetic activity, and the value of the standardised nLF parameter is directly 
proportional to the sympathetic activity. On the other hand, the power of the LF parameter 
depends on both sympathetic and parasympathetic activity (26, 29, 39, 40). Definition of the 
genesis and clinical importance of the VLF component is the most controversial issue. 
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According to the majority of researchers the component is a reflection of the thermoregulative 
activity, RAA system and vascular tonus at rest maintenance (predominantly sympathetically-
mediated) in the HRV spectrum (26, 29, 39, 40). 
Thus, discussing results of our experiment in the perspective of accepted interpretation 
standards, it should be stated that a complete prostaglandin synthesis block with a non-
selective cyclooxygenase inhibitor (piroxicam) caused reduction of the total autonomic 
tension (TP reduction) with a clearly marked decrease of the parasympathetic activity 
(decrease of HF, nHF, HF%). At the same time the functional parasympathetic withdrawal 
was associated with a relative sympathetic predominance (increase of nLF, VLF%). 
The therapy with meloxicam, associated with preferential COX-2 block, also resulted in 
reduction of total activity of the autonomic system, however without the marked functional 
disproportion of any of the two parts of the ANS. Thus, inhibition of synthesis of both 
constitutive (COX-1) and induced (COX-2) prostaglandins caused a reduction of the 
autonomic function, with decreased parasympathetic activity and a relative sympathetic 
predominance, and inhibition of COX-2-mediated prostaglandin synthesis resulted in absence 
of differential effect on activity of both parts of the ANS, although it was also manifested by 
reduction of the total ANS tension. Therefore, it should be expected that constitutive 
prostaglandins (synthesised by COX-1) account for the maintenance of the parasympathetic 
activity and, that way, to increased global ANS activity. However, the application of PGF2α 
analogue (group 2) caused no significant increase of TP and parasympathetically-mediated 
HRV parameters (HF, nHF, partial LF) compared to the control group. However, if results 
obtained for the group 2 are compared to results for the groups 3 and 4 (which was formally 
not performed in the statistical analysis), a clear trend for normalisation of the discussed HRV 
parameters was observed, as expected. That was associated with the expected increase of 
both the total power spectrum and the power of its components LF and HF, percent share of 
those components and increased nHF value.
Moreover, in our opinion, a potentially different effect of various classes of prostaglandins 
in ANS activity modulation should be considered. The presence of prostacyclin (PGI2) as 
well as PGE2 and PGF2 was demonstrated in the human bladder. And conversely, in studies 
on rabbits a predominating character of PGE2 was demonstrated, as a main intravesically 
synthesised prostaglandin. However, considering results of numerous studies it should be 
stated that in physiological and pathophysiological conditions the bladder is a place of 
production and release of four basic classes of prostaglandins: PGE2, PGF2α, PGI2 and 
PGD2 (33). Therefore, our generalised reasoning regarding the role of prostaglandins in 
ANS activity modulation (particularly of the parasympathetic tension) is a cautious one, and 
largely based rather on conclusions from the HRV analysis with a complete blockade of 
synthesis of those compounds, than on direct results obtained for a group of animals treated 
with PGF2α analogue (Enzaprost F5). We assume the existence of a difference in ANS 
modulation ability by various types of prostaglandins, although with a common general 
direction of changes, as suggested by HRV results obtained with a complete and non-selective 
block of all classes of those compounds.
HRV results and conclusions associated with the role of prostaglandin in neurogenic 
bladder control drawn by us are consistent with other reports (18, 27, 36) indicating the role 
of those compounds in generation of bladder overactivity, mediated by activation of receptors 
EP1 and/or EP3 (11, 17, 22). 
Moreover, results of our experiment indicate that increased prostaglandin-dependent 
bladder contractile activity in the model of partial outflow obstruction may be also a result of 
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autonomic activity modulation, with maintenance of the parasympathetic activity. According 
to the commonly accepted concept of the bladder physiology, its neurogenically controlled 
contractile activity results from stimulation of cholinergic receptors M1/M3 (1, 10). 
Therefore, the relative increase of parasympathetic activity may also account for symptoms 
of the bladder contractile overactivity in course of PBOO. At the same time, the fact may 
support the use of cyclooxygenase inhibitors (NSAID) in that illness (in the clinical sense 
– in BPH) as compounds that are able to correct the cholinergically-mediated bladder 
overactivity. As mentioned in the introduction, there are results of clinical trials indicating a 
potential effectiveness of NSAID in BPH (3, 14, 38). That effectiveness is also confirmed in 
some experimental studies – e.g. aspirin administered intravesically to rabbits with the 
experimental PBOO model caused a diminished contractile response to cholinergic 
stimulation (20).
Therefore, our results may support the hypothesis that the beneficial effect of NSAID on 
the bladder function in BPH may be not only a result of absence of EP1/EP3 receptors 
activation in conditions of blocked prostaglandin synthesis, but also of a reduced 
parasympathetic activity. On the other hand, our results are not clearly consistent with results 
obtained by Park et al. (30, 31), who demonstrated increased activity of the COX-2 isoform 
in PBOO conditions. Meloxicam-blocked COX-2 activity demonstrated in our experiment 
had a less pronounced effect on the ANS function compared to piroxicam. That allowed 
formulation of a hypothesis of a dominating role of constitutive prostaglandins (synthesised 
by COX-1), contrary to induced ones (synthesised with COX-2, and dominating according to 
Park et al. (30, 31) in PBOO) in modulation of the autonomic activity. 
There is also a question of the effect of the study compounds on both bladder contractility 
and histological presentation of bladders in groups of animals, that is not completely 
consistent with expectations. A potential efficacy of NSAID on improved bladder function in 
PBOO was not reflected in either bladder compliance or the histological evaluation. Although 
in the bladder weight analysis we have demonstrated the lower BWW value in the group 4 
(PBOO + PRX), suggesting indirectly a lower level of oedema, but in the group of animals 
treated with meloxicam – contrary to conclusions drawn by Park et al. (30, 31), BWW 
reached similar values as in the control group, despite blocking of the potentially dominating 
in PBOO COX-2 isoform. Moreover, the analysis of the BWW/final body weight ratio gave 
the opposite results, indicating a favourable effect of MLX, but not of PRX, on the bladder 
histology. Also, the histopathological description of bladders in each of the study groups, 
described above in Results section, indicated persistence of pathological histological changes 
despite administration of MLX or PRX. In our opinion, the above-mentioned discrepancies 
regarding the absence of expected favourable MLX/PRX effect on the bladder tissue are the 
result of a massive difference in final body weight of animals in groups 3 and 4, on one hand, 
and of short duration of the therapy, on the other. The urodynamic studies did not reveal any 
essential improvement in bladder functioning in any of the treated groups, although PRX 
administration seemed to slightly ameliorate bladder overactivity. The lack of the expected 
influence of the studied agents on the bladder motility may also result from the route of 
administration (we evaluated urodynamic parameters after the studied compounds were 
administered consistently i.p., not intravesically), as well as from the dosing regimen. Short 
treatment with the accepted dosage regimen was probably sufficient for generation of the 
ANS functional changes, but insufficient to cause some structural and physiological changes 
in bladder tissues. However, we tried to apply the doses of the studied agents in accordance 
with the literature reports. The choice of PGF2α dose was based on reports published by 
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Arend et al. (4), who used the dose of 250  µg/kg twice daily, which corresponded to 
approximately 125  µg/rat. On the other hand, Hernandez et al. (16) used the dose of 400µg/
rat, and found the dose to be a large, luteolytic PGF2 α dose. Therefore, we had decided to 
administer 200 µg of PGF2 α prostaglandin analogue solution to animals in group 2, according 
to the adopted dosage frequency. The selection of the meloxicam dose of 5  mg/kg b.w. was 
based on reports published by Laird et al. (21), who used the compound in rats at doses of 
0.1–4mg/kg b.w., every day for 5 days, and on the report published by Bourque et al. (7), who 
administered MLX at the dose of 1–2 mg/kg b.w. every day for 3 days, subcutaneously. 
Therefore, we had concluded that the meloxical administration regimen involving i.p. injec-
tions of 5  mg/kg b.w. of the drug every other day would finally be a similar dosage. In case 
of group 4 we have used the dose of 10  mg/kg b.w. piroxicam, considering experience of 
other researchers who used PRX at doses of 10  mg/kg b.w. (9) or 5  mg/approx. 400g rat (37).
We are aware of limitations of our reasoning regarding evaluation of the ANS activity 
based solely on the indirect HRV method. Moreover, as mentioned above, our reasoning 
regarding the effect of the studied PGF2α analogue on the global ANS activity and the 
parasympathetic part was cautiously referred to the whole group of prostaglandins. We have 
studied PGF2α alone (treating that class of compounds as representative bladder 
prostaglandins), but there are reports indicating species-related differences in synthesis of 
individual prostanoids. Maybe there are also various physiological aspects of the paracrine, 
intravesical activity of those compounds in relation to their effect on the ANS (although 
review of the literature confirms stimulatory effect of various prostaglandin classes on the 
bladder contractile activity). However, considering our overall results of HRV changes in 
PBOO rats obtained in conditions of a total, non-selective or partial COX blockade, and after 
administration of the PGF2α analogue, in our opinion the hypothesis of modulating effect of 
COX-1 synthesised prostaglandins on the parasympathetic activity appears highly probable. 
Moreover, the hypothesis sanctions the validity of research on NSAID applicability in BPH. 
Our results indicate some additional, potentially important elements of pharmacodynamics 
of those drugs, allowing better understanding of their beneficial effect in pharmacotherapy of 
that illness.
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